Current and Future Prospective of a Versatile Moiety: Imidazole

Author(s): Nidhi Rani*, Praveen Kumar, Randhir Singh, Damião P. de Sousa, Prerna Sharma

Journal Name: Current Drug Targets

Volume 21 , Issue 11 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Imidazole containing compounds have been a very much explored field since ancient times. Subsequently, it constitutes a significant moiety for the new drug development. A variety of compounds having imidazole moiety have been synthesized, evaluated and marketed for the treatment of various diseases such as antifungal, antiepileptic, ACE inhibitors and so on, as shown in the figure. The search for imidazole containing compounds with more selective biological potency with low side effects continues to be an active area of research in medicinal chemistry. This review is in an effort to highlight the marketed drugs with imidazole ring. The article also demonstrates the future prospective of marketed imidazoles as antifungal with potential activity targeting 14α-demethylase enzyme.

Keywords: Azole heterocycle, imidazole, marketed imidazole drug, cytochrome P450, 14α-demethylase, enzyme.

[1]
Neochoritis C, Tsoleridis CA, Stephanidou-Stephanatou J. Convenient synthesis of polybrominated imidazole building blocks. ARKIVOC 2007; XV: 101-11.
[2]
Sadjadi S, Heravi MM, Poormohammad N, Oskooie HA, Beheshtiha Y, Bamoharram FF. Direct oxidative conversion of benzoyl chlorides to 2-imidazoles using heteropolyacids. Synth Commun 2009; 39: 3119-25.
[http://dx.doi.org/10.1080/00397910902730978]
[3]
Kidwai M, Kukreja S, Rastogi S, Singhal K. Environmentally benign approach to imidazole-2-thiones. Indian J Chem 2007; 46B: 1549-53.
[4]
Shaabani A, Maleki A, Behnam M. Tandem oxidation process using ceric ammonium nitrate: three-component synthesis of trisubstituted imidazoles under aerobic oxidation conditions. Synth Commun 2009; 39: 102-10.
[http://dx.doi.org/10.1080/00397910802369661]
[5]
Boiani M, González M. Imidazole and benzimidazole derivatives as chemotherapeutic agents. Mini Rev Med Chem 2005; 5(4): 409-24.
[http://dx.doi.org/10.2174/1389557053544047] [PMID: 15853629]
[6]
Wright SW, Harris RR, Collins RJ, et al. Novel 1-(pyridylphenyl)-1-phenyl-2-imidazolylethanols with topical antiinflammatory activity. J Med Chem 1992; 35(17): 3148-55.
[http://dx.doi.org/10.1021/jm00095a009] [PMID: 1507204]
[7]
Grassmann S, Sadek B, Ligneau X, et al. Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H(3)-receptor antagonists. Eur J Pharm Sci 2002; 15(4): 367-78.
[http://dx.doi.org/10.1016/S0928-0987(02)00024-6] [PMID: 11988398]
[8]
Soujanya Y, Sastry GN. Theoretical elucidation of the antioxidant mechanism of 1,3-dihydro-1-methyl-2H-imidazole-2-selenol (Msei). Tetrahedron Lett 2007; 48: 2109-12.
[http://dx.doi.org/10.1016/j.tetlet.2007.01.131]
[9]
Chen J, Wang Z, Lu Y, Dalton JT, Miller DD, Li W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorg Med Chem Lett 2008; 18(11): 3183-7.
[http://dx.doi.org/10.1016/j.bmcl.2008.04.073] [PMID: 18477505]
[10]
Das P, Himaja M. Design and synthesis of 4-[2′-(5′-nitro)]imidazolylbenzoyl(N-methyl)aminoacids and peptides. Int. J. Drug Develop. Res 2010; 2(2): 364-70.
[11]
Ferreira SB, Costa MS, Boechat N, et al. Synthesis and evaluation of new difluoromethyl azoles as antileishmanial agents. Eur J Med Chem 2007; 42(11-12): 1388-95.
[http://dx.doi.org/10.1016/j.ejmech.2007.02.020] [PMID: 17445951]
[12]
Valdez CA, Tripp JC, Miyamoto Y, et al. Synthesis and electrochemistry of 2-ethenyl and 2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against Giardia lamblia. J Med Chem 2009; 52(13): 4038-53.
[http://dx.doi.org/10.1021/jm900356n] [PMID: 19480409]
[13]
Jain R, Vangapandu S, Jain M, Kaur N, Singh S, Singh PP. Antimalarial activities of ring-substituted bioimidazoles. Bioorg Med Chem Lett 2002; 12(13): 1701-4.
[http://dx.doi.org/10.1016/S0960-894X(02)00289-5] [PMID: 12067541]
[14]
Brimblecombe RW, Duncan WAM, Durant GJ, Emmett JC, Gannellin CR, Parsons ME. Cimetidine- a new-thiourea H2 receptor antagonist. J Int Med Res 1975; 3: 86-92.
[http://dx.doi.org/10.1177/030006057500300205]
[15]
Uçucu O, Karaburun NG, Işikdağ I. Synthesis and analgesic activity of some 1-benzyl-2-substituted-4,5-diphenyl-1H-imidazole derivatives. Farmaco 2001; 56(4): 285-90.
[http://dx.doi.org/10.1016/S0014-827X(01)01076-X] [PMID: 11421256]
[16]
Dominianni SJ, Yen TT. Oral hypoglycemic agents. Discovery and structure-activity relationships of phenacylimidazolium halides. J Med Chem 1989; 32(10): 2301-6.
[http://dx.doi.org/10.1021/jm00130a013] [PMID: 2795602]
[17]
Mano T, Stevens RW, Ando K, et al. Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase. Bioorg Med Chem 2003; 11(18): 3879-87.
[http://dx.doi.org/10.1016/S0968-0896(03)00436-X] [PMID: 12927848]
[18]
Dyck B, Goodfellow VS, Phillips T, et al. Potent imidazole and triazole CB1 receptor antagonists related to SR141716. Bioorg Med Chem Lett 2004; 14(5): 1151-4.
[http://dx.doi.org/10.1016/j.bmcl.2003.12.068] [PMID: 14980654]
[19]
Lange JHM, van der Neut MA, Wals HC, et al. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett 2010; 20(3): 1084-9.
[http://dx.doi.org/10.1016/j.bmcl.2009.12.032] [PMID: 20031412]
[20]
Kiselyov AS, Semenova M, Semenov VV, Piatnitski E, Ouyang S. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett 2006; 16(5): 1440-4.
[http://dx.doi.org/10.1016/j.bmcl.2005.11.033] [PMID: 16321531]
[21]
Blum CA, Zheng X, De Lombaert S. Design, Synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles:[REMOVED HYPERLINK FIELD] potent and selective neuropeptide Y5-receptor antagonists. J Med Chem 2004; 47: 2318-25.
[http://dx.doi.org/10.1021/jm030490g] [PMID: 15084130]
[22]
Nguyen DN, Stump CA, Walsh ES, et al. Potent inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorg Med Chem Lett 2002; 12(9): 1269-73.
[http://dx.doi.org/10.1016/S0960-894X(02)00154-3] [PMID: 11965368]
[23]
Sennequier N, Wolan D, Stuehr DJ. Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem 1999; 274(2): 930-8.
[http://dx.doi.org/10.1074/jbc.274.2.930] [PMID: 9873034]
[24]
Jackson PF, Bullington JL. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr Top Med Chem 2002; 2(9): 1011-20.
[http://dx.doi.org/10.2174/1568026023393372] [PMID: 12171568]
[25]
Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997; 4(6): 423-31.
[http://dx.doi.org/10.1016/S1074-5521(97)90194-0] [PMID: 9224565]
[26]
Bolós J. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. Mini Rev Med Chem 2005; 5(9): 857-68.
[http://dx.doi.org/10.2174/1389557054867048] [PMID: 16178727]
[27]
Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem 2005; 5(10): 953-65.
[http://dx.doi.org/10.2174/1568026054985948] [PMID: 16178740]
[28]
Rani N, Sharma A, Gupta GK, Singh R. Imidazoles as potential antifungal agents: a review. Mini Rev Med Chem 2013; 13(11): 1626-55.
[http://dx.doi.org/10.2174/13895575113139990069] [PMID: 23815583]
[29]
Sharma GVM, Jyothi Y, Lakshmi PS. efficient room-temperature synthesis of tri- and tetrasubstituted imidazoles catalyzed by Zrcl4. Synth Commun 2006; 36: 2991-3000.
[http://dx.doi.org/10.1080/00397910600773825]
[30]
Rani N, Sharma A, Singh R. Imidazoles as promising scaffolds for antibacterial activity: a review. Mini Rev Med Chem 2013; 13(12): 1812-35.
[http://dx.doi.org/10.2174/13895575113136660091] [PMID: 24032508]
[31]
Gupta GK, Rani N, Kumar V. Microwave assisted synthesis of imidazoles: A review. Mini Rev Org Chem 2012; 9: 270-84.
[http://dx.doi.org/10.2174/1570193X11209030270]
[32]
Rani N. synthesis, biological evaluation and computational study of some new imidazole derivatives. m. pharma dissertation, maharishi markandeshwar university, mullana 2011.
[33]
Rani N, Sharma A, Singh R. Trisubstituted imidazole synthesis: A review. Mini Rev Org Chem 2015; 12(1): 34-65.
[http://dx.doi.org/10.2174/1570193X11666141028235010]
[34]
Kathiravan MK, Salake AB, Chothe AS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem 2012; 20(19): 5678-98.
[http://dx.doi.org/10.1016/j.bmc.2012.04.045] [PMID: 22902032]
[35]
Shehabi Y, Botha JA, Ernest D, et al. Clinical application, the use of dexmedetomidine in intensive care sedation. Crit Care Shock 2010; 13: 40-50.
[36]
Bilehjani E, Kianfar AA, Toofan M, Fakhari S. Anesthesia with etomidate and remifentanil for cesarean section in a patient with severe peripartum cardiomyopathy--a case report. Middle East J Anaesthesiol 2008; 19(5): 1141-9.
[PMID: 18637614]
[37]
Block JH, Beale JM. Wilson and Gisvold’s textbook of Organic Medicinal and Pharmaceutical Chemistry. 11th ed. 2004.
[38]
Annane D. ICU physicians should abandon the use of etomidate! Intensive Care Med 2005; 31(3): 325-6.
[http://dx.doi.org/10.1007/s00134-005-2560-1] [PMID: 15750800]
[39]
Lee L. pharmacology - intravenous anesthetic agents & dissociatives veterinary surgery i, vmed 7412 1-14.
[40]
Crosby TC. metomidate hydrochloride as a sedative for transportation of selected ornamental fishes a thesis presented to the graduate school of the university of florida in partial fulfillment of the requirements for the degree of master of science, university of florida 2008.
[41]
Olsen Y, Einarsdottir I, Nilssen K. Metomidate anaesthesia in atlantic salmon, salmo salar, prevents plasma cortisol increase during stress. Aquaculture 1995; 134(1-2): 155-68.
[http://dx.doi.org/10.1016/0044-8486(95)00008-P]
[42]
Ross R, Backman T, Bennett R. Evaluation of the anesthetic metomidate for the handling and transport of juvenile american shad. Prog Fish-Cult 1993; 55(4): 236-43.
[http://dx.doi.org/10.1577/1548-8640(1993)055<0236:EOTAMF>2.3.CO;2]
[43]
Gleadall I. Comparison of anaesthetics for octopuses. Bull Mar Sci 1991; 49(1-2): 663.
[44]
Sandodden R, Finstad B, Iversen M. Transport stress in atlantic salmon (salmosalar l.): anaesthesia and recovery. Aquacult Res 2001; 32(2): 87-90.
[http://dx.doi.org/10.1046/j.1365-2109.2001.00533.x]
[45]
Suwalsky M, Mennickent S, Norris B, Villena F, Cuevas F, Sotomayor CP. The antiepileptic drug diphenylhydantoin affects the structure of the human erythrocyte membrane. Z Natforsch C J Biosci 2004; 59(5-6): 427-31.
[http://dx.doi.org/10.1515/znc-2004-5-625] [PMID: 18998414]
[46]
Ali MS, Singh S, Kumar A, Singh S, Ansari MT, Pattnaik G. Preparation and in vitroevaluation of sustained release matrix tablets of phenytoin sodium using natural polymers. Int J Pharm Pharm Sci 2010; 2(3): 174-9.
[47]
Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64(10): 887-95.
[http://dx.doi.org/10.1016/j.addr.2011.11.006] [PMID: 22210279]
[49]
Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 2003; 42(1): 33-58.
[http://dx.doi.org/10.2165/00003088-200342010-00002] [PMID: 12489978]
[50]
Yeh JS, Dhir JS, Green AL, Bodiwala D, Brydon HL. Changes in plasma phenytoin level following craniotomy. Br J Neurosurg 2006; 20(6): 403-6.
[http://dx.doi.org/10.1080/02688690601101440] [PMID: 17439093]
[51]
Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Kokwaro GO. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol 2002; 54(6): 635-42.
[PMID: 12492612]
[52]
Snead C, Siegel N, Hayslett J. Generalized lymphadenopathy and nephrotic syndrome as a manifestation of mephenytoin (mesantoin) toxicity. Pediatrics 1976; 57(1): 98-101.
[PMID: 1246508]
[53]
Allen JD, Ekue JM, Shanks RG, Zaidi SA. The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol 1972; 45(4): 561-73.
[http://dx.doi.org/10.1111/j.1476-5381.1972.tb08114.x] [PMID: 5085230]
[54]
Dwivedi R, Gogtay N, Kharkar V, Amladi S, Kshirsagar N. In-vitro lymphocyte toxicity to a phenytoin metabolite in phenytoin induced cutaneous adverse drug eruptions. Indian J Dermatol Venereol Leprol 2004; 70(4): 217-20.
[PMID: 17642618]
[55]
Mirzai H, Baser EF. Congenital Horner’s syndrome and the usefulness of the apraclonidine test in its diagnosis. Indian J Ophthalmol 2006; 54(3): 197-9.
[http://dx.doi.org/10.4103/0301-4738.27073] [PMID: 16921219]
[56]
Searles RV, Shikher V, Balaban CD, Severs WB. Aqueous humor dynamics in anesthetized rats infused with intracameral apraclonidine. Pharmacology 1999; 58(4): 220-6.
[http://dx.doi.org/10.1159/000028284] [PMID: 10077741]
[57]
Silvestre JF, Carnero L, Ramón R, Albares MP, Botella R. Allergic contact dermatitis from apraclonidine in eyedrops. Contact Dermat 2001; 45(4): 251.
[http://dx.doi.org/10.1034/j.1600-0536.2001.450421.x] [PMID: 11683848]
[58]
Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998; 12(3): 225-41.
[http://dx.doi.org/10.2165/00002512-199812030-00005] [PMID: 9534022]
[59]
Meston CM, Gorzalka BB, Wright JM. Inhibition of subjective and physiological sexual arousal in women by clonidine. Psychosom Med 1997; 59(4): 399-407.
[http://dx.doi.org/10.1097/00006842-199707000-00010] [PMID: 9251160]
[60]
Basker S, Singh G, Jacob R. Clonidine in paediatrics - a review. Indian J Anaesth 2009; 53(3): 270-80.
[PMID: 20640134]
[61]
L’Ami JJ, Vermunt LE, van Loon JP, Sloet van Oldruitenborgh-Oosterbaan MM. Sublingual administration of detomidine in horses: sedative effect, analgesia and detection time. Vet J 2013; 196(2): 253-9.
[http://dx.doi.org/10.1016/j.tvjl.2012.08.016] [PMID: 23062724]
[62]
Kariman A, Sharifi D, Nowrouzian I. Evaluation of detomidine hydrochloride, diazepam and thiopental sodium combination on cardiovascular function and hemodynamics in sheep. Small Rumin Res 1998; 29: 43-9.
[http://dx.doi.org/10.1016/S0921-4488(97)00104-1]
[63]
Lee D, Yun S, Cho K, Lee H, Choi Y. A case of naphazoline intoxication after the ingestion of a topical antiseptic solution. Hong Kong J Emerg Med 2010; 17(4): 364-6.
[http://dx.doi.org/10.1177/102490791001700409]
[64]
Meloun M, Syrový T, Vrána A. The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. Talanta 2004; 62(3): 511-22.
[http://dx.doi.org/10.1016/j.talanta.2003.08.027] [PMID: 18969326]
[65]
Beck-Speier I, Dayal N, Karg E, et al. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites. J Pharmacol Exp Ther 2006; 316(2): 843-51.
[http://dx.doi.org/10.1124/jpet.105.093278] [PMID: 16221739]
[66]
Ticoll B, Shugar G. Paranoid psychosis induced by oxymetazoline nasal spray. CMAJ 1994; 150(3): 375-6.
[PMID: 8293377]
[67]
Khan MA, Khan AA, Faruqi NA. Azelastine and xylometazoline-induced microscopic changes in the nasal mucosa and olfactory bulb. J Anat Soc 2005; 54(2): 18-21.
[68]
Grigolcit H. Oxymetazoline in allergic rhinitis: a review of controlled clinical trials. J Chin Clin Med 2006; 1(7): 411-7.
[69]
Spiller HA, Rogers J, Sawyer TS. Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine). Leg Med (Tokyo) 2007; 9(4): 192-5.
[http://dx.doi.org/10.1016/j.legalmed.2007.01.005] [PMID: 17320456]
[70]
Neistadt I. Clinical trial of tetrahydrozoline hydrochloride; a valuable new nasal decongestant. AMA Arch Otolaryngol 1955; 62(2): 143-4.
[http://dx.doi.org/10.1001/archotol.1955.03830020025005] [PMID: 14397923]
[71]
Huang M, Ho H, Wen K, Sheu M. High performance liquid chromatography analysis of tetrahydrozoline hydrochloride in ophthalmic solution by silica column eluted with aqueous solvent mixtures. Yao Wu Shi Pin Fen Xi 2002; 10(2): 88-94.
[72]
Chusid E, Lehr D, Levy W. Severe respiratory depression following nasal instillation of tetrahydrozoline hydrochloride. J Pediatr 1956; 48(1): 66-9.
[http://dx.doi.org/10.1016/S0022-3476(56)80119-4] [PMID: 13295949]
[73]
Saper JR, Winner PK, Lake AE III. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache 2001; 41(4): 357-68.
[http://dx.doi.org/10.1046/j.1526-4610.2001.111006357.x] [PMID: 11318882]
[74]
freedom of information summary nada, antisedan 2006.
[75]
Brynne L, Mcnay JL, Schaefer HG, Swedberg K, Wiltse CG, Karlsson MO. Phramacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. Clin Pharmacol 2000; 51: 35-43.
[http://dx.doi.org/10.1046/j.1365-2125.2001.01320.x]
[76]
Schachter M. Metabolic effects of moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab 1999; 1(6): 317-22.
[http://dx.doi.org/10.1046/j.1463-1326.1999.00042.x] [PMID: 11225647]
[77]
Aarnoudse W, Geven M, Barbato E, Botman KJ, De Bruyne B, Pijls NHJ. Effect of phentolamine on the hyperemic response to adenosine in patients with microvascular disease. Am J Cardiol 2005; 96(12): 1627-30.
[http://dx.doi.org/10.1016/j.amjcard.2005.07.078] [PMID: 16360347]
[78]
Rosen RC, Phillips NA, Gendrano NC III, Ferguson DM. Oral phentolamine and female sexual arousal disorder: a pilot study. J Sex Marital Ther 1999; 25(2): 137-44.
[http://dx.doi.org/10.1080/00926239908403987] [PMID: 10327383]
[79]
Kiel JW, Reitsamer HA. Paradoxical effect of phentolamine on aqueous flow in the rabbit. J Ocul Pharmacol Ther 2007; 23(1): 21-6.
[http://dx.doi.org/10.1089/jop.2006.0102] [PMID: 17341146]
[80]
Yasukawa M, Yasukawa K, Kamiizumi Y, Yokoyama R. Intravenous phentolamine infusion alleviates the pain of abdominal visceral cancer, including pancreatic carcinoma. J Anesth 2007; 21(3): 420-3.
[http://dx.doi.org/10.1007/s00540-007-0528-8] [PMID: 17680199]
[81]
Bush A, Busst CM, Knight WB, Shinebourne EA. Cardiovascular effects of tolazoline and ranitidine. Arch Dis Child 1987; 62(3): 241-6.
[http://dx.doi.org/10.1136/adc.62.3.241] [PMID: 3566316]
[82]
Park KI, Namgung R, Lee C, Han DG. Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease. Yonsei Med J 1990; 31(2): 156-62.
[http://dx.doi.org/10.3349/ymj.1990.31.2.156] [PMID: 2219973]
[83]
Csuk R, Woeste B. A chemoenzymatic approach to (+)-pilocarpine. Tetrahedron 2008; 64: 9384-7.
[http://dx.doi.org/10.1016/j.tet.2008.07.100]
[84]
nervous system agents 6th ed. abraham dj. burger’s medicinal chemistry and drug discovery62003
[85]
Smith SA, Smith SE, Lazare R. An increased effect of pilocarpine on the pupil by application of the drug in oil. Br J Ophthalmol 1978; 62(5): 314-7.
[http://dx.doi.org/10.1136/bjo.62.5.314] [PMID: 656357]
[86]
Navarro Mora G, Bramanti P, Osculati F, et al. Does pilocarpine-induced epilepsy in adult rats require status epilepticus? PLoS One 2009; 4(6)e5759
[http://dx.doi.org/10.1371/journal.pone.0005759] [PMID: 19503612]
[87]
Downar E, Waxman MB. Antazoline therapy of recurrent refractory supraventricular arrhythmias--a preliminary report. Can Med Assoc J 1975; 113(5): 391-3.
[PMID: 1098755]
[88]
Jantratid E, Prakongpan S, Dressman JB, et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J Pharm Sci 2006; 95(5): 974-84.
[http://dx.doi.org/10.1002/jps.20614] [PMID: 16557528]
[89]
Moreno RA, Oliveria C, Brum JL, et al. Cimetidine quantification in human plasma by high performance liquid chromatography coupled to electrospray ionization tandem mass spectrometry. Application to a comapartive pharmacokinetics study. J Bioanal Biomed 2009; 1(1): 5-13.
[90]
Barbezat GO, Grant B, Bank S, Vinik A. The effect of histamine H2-receptor blockade with metiamide on serum gastrin levels in man. Gut 1975; 16(3): 186-7.
[http://dx.doi.org/10.1136/gut.16.3.186] [PMID: 1123173]
[91]
Bird TL, Larkin MM, Betton GR. Toxic effects of the histamine H(2) receptor antagonist metiamide on bone-marrow haemopoietic and stromal progenitor cells in vitro. Toxicol In Vitro 1988; 2(3): 221-4.
[http://dx.doi.org/10.1016/0887-2333(88)90011-2] [PMID: 20702338]
[92]
Blankestijn PJ, Rupp H. Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem 2008; 6(4): 253-7.
[http://dx.doi.org/10.2174/187152508785909500] [PMID: 18855637]
[93]
Schrader J, Lüders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36(6): 1218-26.
[http://dx.doi.org/10.1161/01.STR.0000166048.35740.a9] [PMID: 15879332]
[94]
Ers HN, Gogas-Yayuz D, Zdouan O, Budak Y, Akalyn S. The effect of losartan on plasma atrial natriuretic peptide levels in the diabetic. rat model. Turkish. J Endocrinol Metab 1999; 1: 17-22.
[95]
Rout PK, Nayak BS, Nayak UK. The effect of losartan on plasma atrial natriuretic peptide levels in the diabetic. rat model Turkish. J Endocrinol Metab 2009; 1: 17-22.
[96]
Norwood D, Branch E, Smith B, Honeywell M. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast 2002; 27(12): 611-8.
[97]
Aletrari M, Kanari P, Partassides D, Loizou E. Study of the British Pharmacopeia method on methimazole (thiamazole) content in carbimazole tablets. J Pharm Biomed Anal 1998; 16(5): 785-92.
[http://dx.doi.org/10.1016/S0731-7085(97)00119-2] [PMID: 9535190]
[98]
Economou A, Tzanavaras PD, Notou M, Themelis DG. Determination of methimazole and carbimazole by flow-injection with chemiluminescence detection based on the inhibition of the Cu(II)-catalysed luminol–hydrogen peroxide reaction. Anal Chim Acta 2004; 505: 129-33.
[http://dx.doi.org/10.1016/S0003-2670(03)00176-4]
[99]
Khan ZK, Jain P. Antifungal agents and immunomodulators in systemic mycoses. Indian J Chest Dis Allied Sci 2000; 42(4): 345-55.
[PMID: 15597684]
[100]
Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health--chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther 2003; 26(1): 5-29.
[http://dx.doi.org/10.1046/j.1365-2885.2003.00456.x] [PMID: 12603774]
[101]
Marriott MS. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J Gen Microbiol 1980; 117(1): 253-5.
[PMID: 6993625]
[102]
Lackner TE, Clissold SP. Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1989; 38(2): 204-25.
[http://dx.doi.org/10.2165/00003495-198938020-00004] [PMID: 2670516]
[103]
Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988; 1(2): 187-217.
[http://dx.doi.org/10.1128/CMR.1.2.187] [PMID: 3069196]
[104]
Menozzi G, Merello L, Fossa P, et al. Synthesis, antimicrobial activity and molecular modeling studies of halogenated 4-[1H-imidazol-1-yl(phenyl)methyl]-1,5-diphenyl-1H-pyrazoles. Bioorg Med Chem 2004; 12(20): 5465-83.
[http://dx.doi.org/10.1016/j.bmc.2004.07.029] [PMID: 15388173]
[105]
Rotstein DM, Walker KAM. The synthesis and antifungal activity of the enantiomers of butaconazole nitrate. Tetrahedron:Assym 1993; 4(7): 1521-6.
[http://dx.doi.org/10.1016/S0957-4166(00)80353-5]
[106]
Kidwai M, Venkataramanan R, Rastogi S, Sapra P. Discovery and development of antifungal compounds. Curr Med Chem 2003; 2: 27-71.
[107]
Couteau C, Jaduad M, Peigne F, Coiffard LJM. Influence of pH on the photodegradation kinetics under UV light of climbazole solutions. Analusis 2000; 28: 557-60.
[http://dx.doi.org/10.1051/analusis:2000171]
[108]
Yang W, Li J, Chen Q, Yang G. Novel synthetic methods for N-cyano-1H-imidazole-4-carboxamides and their fungicidal activity. Bioorg Med Chem Lett 2011.
[http://dx.doi.org/10.1016/j.bmcl.2011.11.115] [PMID: 22189134]
[109]
Abu-Jdayil B, Mohameed HA. Rheology of Dead Sea shampoo containing the antidandruff climbazole. Int J Cosmet Sci 2004; 26(6): 281-9.
[http://dx.doi.org/10.1111/j.1467-2494.2004.00240.x] [PMID: 18492152]
[110]
Vanitha J, Kumar AS, Ganesh M, Sarvanan VS. Comaparative analysis of climbazole in pharmaceutical formulation. Asian J Res Chem 2008; 1(1): 43-5.
[111]
Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother 1984; 25(4): 450-4.
[http://dx.doi.org/10.1128/AAC.25.4.450] [PMID: 6375555]
[112]
Beierdörffer H, Michel G, Kehr K. Croconazole in the treatment of tinea pedis. Mycoses 1995; 38(11-12): 501-7.
[http://dx.doi.org/10.1111/j.1439-0507.1995.tb00028.x] [PMID: 8720204]
[113]
Barbanoj MJ, Antonijoan R, García-Gea C, Puntes M, Gich I, Jané F. Eberconazole cream: topical and general tolerability, sensitisation potential, and systemic availability. Methods Find Exp Clin Pharmacol 2005; 27(4): 227-34.
[http://dx.doi.org/10.1358/mf.2005.27.4.893581] [PMID: 16082423]
[114]
Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR. Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream. Int J Dermatol 2006; 45(5): 600-4.
[http://dx.doi.org/10.1111/j.1365-4632.2006.02841.x] [PMID: 16700802]
[115]
Torres-Rodríguez JM, Mendez R, López-Jodra O, et al. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrob Agents Chemother 1999; 43(5): 1258-9.
[http://dx.doi.org/10.1128/AAC.43.5.1258] [PMID: 10223946]
[116]
Heel RC, Brogden RN, Speight TM, Avery GS. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs 1978; 16(3): 177-201.
[http://dx.doi.org/10.2165/00003495-197816030-00001] [PMID: 98315]
[117]
Hnilica KA, Medleau L. Evaluation of topically applied enilconazole for the treatment of dermatophytosis in a Persian cattery. Vet Dermatol 2002; 13(1): 23-8.
[http://dx.doi.org/10.1046/j.0959-4493.2001.00282.x] [PMID: 11896967]
[118]
Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother 1989; 33(6): 970-2.
[http://dx.doi.org/10.1128/AAC.33.6.970] [PMID: 2764547]
[119]
Veraldi S, Milani R. Topical fenticonazole in dermatology and gynaecology: current role in therapy. Drugs 2008; 68(15): 2183-94.
[http://dx.doi.org/10.2165/00003495-200868150-00007] [PMID: 18840006]
[120]
Pfaller MA. A clinical review of antibacterial, antifungal and antiviral drugs Kucers! the use of antibiotics 6th ed. 2010.
[121]
del Palacio Cuétara S. izquierdo i, et al A double-blind, randomized comparative trial: flutrimazole 1% solution versus bifonazole 1% solution once daily in dermatomycoses. Mycoses 1995; 38(9-10): 395-403.
[http://dx.doi.org/10.1111/j.1439-0507.1995.tb00071.x] [PMID: 8569816]
[122]
Rigopoulos D, Gregoriou S, Kontochristopoulos G, Ifantides A, Katsambas A. Flutrimazole shampoo 1% versus ketoconazole shampoo 2% in the treatment of pityriasis versicolor. A randomised double-blind comparative trial. Mycoses 2007; 50(3): 193-5.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01352.x] [PMID: 17472615]
[123]
Dhawale SC, Ranpise HA, Sanap DK, Mathure DM, Ranpise AA. Formulation development and in vitro evaluation of PLGA nanoparticles of flutrimazole. Int J Univ Pharm Bio Sci 2013; 2(5): 310-26.
[124]
Cohen L. Single dose treatment of vaginal candidosis: comparison of clotrimazole and isoconazole. Br J Vener Dis 1984; 60(1): 42-4.
[http://dx.doi.org/10.1136/sti.60.1.42] [PMID: 6365236]
[125]
Agah S, Fereshtehnejad S, Yousefnejad A, Siavashi F. Antimicrobial activity of ketoconazole and fluconazole against metronidazole resistance strains of Helicobacter pylori. Int J Pharm Tech 2008; 7: 57-60.
[126]
Leun CY. Antifungal therapy in dermatology. J Hong Kong Med Assoc 1990; 42(4): 203-5.
[127]
Furukawa K, Sasaki H, Pollard RB, Suzuki F. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. J Antimicrob Chemother 2000; 46(3): 443-50.
[http://dx.doi.org/10.1093/jac/46.3.443] [PMID: 10980172]
[128]
Niwano Y, Ohmi T, Seo A, Kodama H, Koga H, Sakai A. Lanoconazole and its related optically active compound nnd-502:novel antifungal imidazoles with a ketene dithioacetal structure. Curr Med Anti Infect Agents 2003; 2: 147-60.
[http://dx.doi.org/10.2174/1568012033483097]
[129]
Niwano Y, Tabuchi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent. Antimicrob Agents Chemother 1995; 39(10): 2353-5.
[http://dx.doi.org/10.1128/AAC.39.10.2353] [PMID: 8619597]
[130]
Tanaka T, Satoh T, Yokozeki H. Allergic contact dermatitis from luliconazole: implication of the dithioacetal structure 2006; 271-2.
[131]
Watanabe S, Takahashi H, Nishikawa T, et al. Dose-finding comparative study of 2 weeks of luliconazole cream treatment for tinea pedis--comparison between three groups (1%, 0.5%, 0.1%) by a multi-center randomised double-blind study. Mycoses 2007; 50(1): 35-40.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01305.x] [PMID: 17302746]
[132]
Watanabe S, Takahashi H, Nishikawa T, et al. A comparative clinical study between 2 weeks of luliconazole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses 2006; 49(3): 236-41.
[http://dx.doi.org/10.1111/j.1439-0507.2006.01218.x] [PMID: 16681817]
[133]
Shono M. Allergic contact dermatitis from luliconazole. Contact Dermat 2007; 56(5): 296-7.
[http://dx.doi.org/10.1111/j.1600-0536.2006.01023.x] [PMID: 17441865]
[134]
Kazy Z, Puhó E, Czeizel AE. The possible association between the combination of vaginal metronidazole and miconazole treatment and poly-syndactyly Population-based case-control teratologic study. Reprod Toxicol 2005; 20(1): 89-94.
[http://dx.doi.org/10.1016/j.reprotox.2004.11.012] [PMID: 15808791]
[135]
Tatsumi Y, Yokoo M, Arika T, Yamaguchi H. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother 2001; 45(5): 1493-9.
[http://dx.doi.org/10.1128/AAC.45.5.1493-1499.2001] [PMID: 11302816]
[136]
Ogura H, Kobayashi H, Nagai K, et al. Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents. Chem Pharm Bull (Tokyo) 1999; 47(10): 1417-25.
[http://dx.doi.org/10.1248/cpb.47.1417] [PMID: 10553638]
[137]
Uchida K, Itoyama T, Yamaguchi H. [in vitro antifungal activity of omoconazole nitrate, a novel imidazone antimycotic drug, against clinical isolates from patients with cutaneous mycosis]. Jpn J Antibiot 1996; 49(8): 818-23.
[PMID: 9053537]
[138]
Itoyama T, Uchida K, Yamaguchi H, Fujita S. Therapeutic effects of omoconazole nitrate on experimental tinea pedis, an intractable dermatophytosis, in guinea-pigs. J Antimicrob Chemother 1997; 40(3): 441-4.
[http://dx.doi.org/10.1093/jac/40.3.441] [PMID: 9338501]
[139]
Rossello A, Bertini S, Lapucci A, et al. Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole. J Med Chem 2002; 45(22): 4903-12.
[http://dx.doi.org/10.1021/jm020980t] [PMID: 12383016]
[140]
Wistreich GA. candidiasis and cryptococcosis: two costly healthcare burdens rc educational consultingservices, inc
[141]
Chitescu CL, Nicolau A. Another point of view on side effects of antifungal compounds used in veterinary medicine. Vet Drug 2011; 5(1): 68-74.
[142]
Ford MM. Antifungals and their use in veterinary ophthalmology. Vet Clin North Am Small Anim Pract 2004; 34(3): 669-91.
[http://dx.doi.org/10.1016/j.cvsm.2003.12.002] [PMID: 15110978]
[143]
Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs 2009; 69(3): 339-59.
[http://dx.doi.org/10.2165/00003495-200969030-00009] [PMID: 19275277]
[144]
Benfield P, Clissold SP. Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 2009; 69(3): 339-59.
[PMID: 19275277]
[145]
Clissold SP, Heel RC. Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs 1986; 31(1): 29-51.
[http://dx.doi.org/10.2165/00003495-198631010-00003] [PMID: 3510114]
[146]
Ganjali MR, Norouzi P, Faridbod F, Pirelahi H. Novel metronidazole membrane sensor based on a 2,6-(p-N,N-dimethylaminophenyl)-4-phenylthiopyrylium perchlorate. J Chin Chem Soc (Taipei) 2007; 54: 55-61.
[http://dx.doi.org/10.1002/jccs.200700010]
[147]
Singh PP, Jain H. Trichomoniasis: chemotherapy, drug-resistance and new targets. J Parasit Dis 2007; 31(2): 79-91.
[148]
Cantelli-Forti G, Paolini M, Hrelia P, Sapigni E, Biagi GL. Effects of metronidazole, azanidazole, and azathioprine on cytochrome P450 and various mono-oxygenase activities in hepatic microsomes from control and induced mice. Arch Toxicol Suppl 1987; 11: 264-9.
[http://dx.doi.org/10.1007/978-3-642-72558-6_48] [PMID: 3477179]
[149]
Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64(6): 1139-47.
[http://dx.doi.org/10.1093/jac/dkp357] [PMID: 19819909]
[150]
Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas’ disease in adults. Antimicrob Agents Chemother 2010; 54(11): 4896-9.
[http://dx.doi.org/10.1128/AAC.00537-10] [PMID: 20823286]
[151]
Notowicz A, Stolz E, de Koning GA. First experiences with single-dose treatment of vaginal trichomoniasis with carnidazole (R 25831). Br J Vener Dis 1977; 53(2): 129-31.
[http://dx.doi.org/10.1136/sti.53.2.129] [PMID: 322823]
[152]
Fernie DS, Ware DA, Park RW. The effect of the nitroimidazole drug dimetridazole on microaerophilic campylobacters. J Med Microbiol 1977; 10(2): 233-40.
[http://dx.doi.org/10.1099/00222615-10-2-233] [PMID: 558335]
[153]
Tweit RC, Kreider EM, Muir RD. Synthesis of antimicrobial nitroimidazolyl 2-sulfides, -sulfoxides, and -sulfones. J Med Chem 1973; 16(10): 1161-9.
[http://dx.doi.org/10.1021/jm00268a021] [PMID: 4201423]
[154]
Moeller MW. Effect of dimetridazole on rate of gain and feed efficiency in swine. J Anim Sci 1967; 26(1): 64-6.
[http://dx.doi.org/10.2527/jas1967.26164x] [PMID: 6031645]
[155]
Ho C, Sin DWM, Wong KM, Tang HPO. Determination of dimetridazole and metronidazole in poultry and porcine tissues by gas chromatography–electron capture negative ionization mass spectrometry. Anal Chim Acta 2005; 530: 23-31.
[http://dx.doi.org/10.1016/j.aca.2004.09.004]
[156]
Bendesky A, Menéndez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002; 511(2): 133-44.
[http://dx.doi.org/10.1016/S1383-5742(02)00007-8] [PMID: 12052431]
[157]
El-Kamel AH, Ashri LY, Alsarra IA. Micromatricial metronidazole benzoate film as a local mucoadhesive delivery system for treatment of periodontal diseases. AAPS PharmSciTech 2007; 8(3)E75
[http://dx.doi.org/10.1208/pt0803075] [PMID: 17915825]
[158]
Overgaard J, Eriksen JG, Nordsmark M. ALsner, J.; Horsman, M.R. Plasma Osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA5 randomised double blind placebo-controlled trial. Lancet Oncol 2005; 6: 757-64.
[http://dx.doi.org/10.1016/S1470-2045(05)70292-8] [PMID: 16198981]
[159]
Reynolds AV, Hamilton-Miller JMT, Brumfitt W. A comparison of the in vitro activity of metronidazole, tinidazole, and nimorazole against Gram-negative anaerobic bacilli. J Clin Pathol 1975; 28(10): 775-8.
[http://dx.doi.org/10.1136/jcp.28.10.775] [PMID: 1214009]
[160]
Solbach W, Wagner H, Röllinghoff M. Effect of niridazole in cellular immunity in vivo and in vitro. Clin Exp Immunol 1978; 32(3): 411-8.
[PMID: 357051]
[161]
Rudofsky UH, Pollara B. Studies on the pathogenesis of experimental autoimmune renal tubulointerstitial disease in guinea-pigs. IV. failure to inhibit mononuclear cell accumulation with niridazole. Clin Exp Immunol 1977; 27(3): 522-5.
[PMID: 862238]
[162]
Barat R, Srinatha A, Pandit JK, Mittal N, Anupurba S. Ethylcellulose inserts of an orphan drug for periodontitis: preparation, in vitro, and clinical studies. Drug Deliv 2007; 14(8): 531-8.
[http://dx.doi.org/10.1080/10717540701606517] [PMID: 18027183]
[163]
Simen YH, Zeynep AY, Mine O. Bioavailability file: ornidazole. FABAD J Pharm Sci 2004; 29: 133-44.
[164]
Gookin JL, Copple CN, Papich MG, et al. Efficacy of ronidazole for treatment of feline Tritrichomonas foetus infection. J Vet Intern Med 2006; 20(3): 536-43.
[http://dx.doi.org/10.1111/j.1939-1676.2006.tb02893.x] [PMID: 16734086]
[165]
Davidson GS. Ronidazole in the treatment of trichomonad infections in cats. Int J Pharm Compd 2006; 10(6): 434-5.
[PMID: 23974416]
[166]
Sams MJ, Strutt PR, Barnes KA, Damant AP, Rose MD. Determination of dimetridazole, ronidazole and their common metabolite in poultry muscle and eggs by high performance liquid chromatography with UV detection and confirmatory analysis by atmospheric pressure chemical ionisation mass spectrometry. Analyst (Lond) 1998; 123(12): 2545-9.
[http://dx.doi.org/10.1039/a805204b] [PMID: 10435296]
[167]
Rosenblum C, Trenner NR, Buhs RP, Hiremath CB, Koniuszy FR, Wolf DE. Metabolism of ronidazole (1-methyl-5-nitroimidazol-2-ylmethyl carbamate). J Agric Food Chem 1972; 20(2): 360-71.
[http://dx.doi.org/10.1021/jf60180a053] [PMID: 5016619]
[168]
Agrahari V, Bajpai M, Nanda S. Development of simple UV-spectrometric assay method for satranidazole and study of its degradation profile. Int Res J Pharm 2013; 4(4): 209-13.
[http://dx.doi.org/10.7897/2230-8407.04442]
[169]
Bansal K, Rawat MK, Jain A, Rajput A, Chaturvedi TP, Singh S. Development of satranidazole mucoadhesive gel for the treatment of periodontitis. AAPS PharmSciTech 2009; 10(3): 716-23.
[http://dx.doi.org/10.1208/s12249-009-9260-z] [PMID: 19479385]
[170]
Ptel MB, Patel KM, Patel GS. Development and validation of a stability-indicating hptlc-densitometric method for satranidazole. J Liq Chromatogr Relat Technol 2007; 30: 2459-71.
[http://dx.doi.org/10.1080/10826070701465852]
[171]
Kumar P, Rao PYV, Kumar BK, Prasanthi V, Murty BS. Direct spectrometric determination of satranidazole. Int J Pharm Sci Res 2012; 3(9): 3314-6.
[172]
Jiménez JC, Rodríguez N, Di Prisco MC, Lynch NR, Costa V. Haemoglobin concentrations and infection by Giardia intestinalis in children: effect of treatment with secnidazole. Ann Trop Med Parasitol 1999; 93(8): 823-7.
[http://dx.doi.org/10.1080/00034983.1999.11813489] [PMID: 10715676]
[173]
Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol 2010; 2010: 1-6.
[http://dx.doi.org/10.1155/2010/705692] [PMID: 20885970]
[174]
Girginkardeşler N, Coşkun S, Cüneyt Balcioğlu I, Ertan P, Ok UZ. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin Microbiol Infect 2003; 9(2): 110-3.
[http://dx.doi.org/10.1046/j.1469-0691.2003.00504.x] [PMID: 12588330]
[175]
Upcroft JA, Dunn LA, Wright JM, Benakli K, Upcroft P, Vanelle P. 5-Nitroimidazole drugs effective against metronidazole-resistant Trichomonas vaginalis and Giardia duodenalis. Antimicrob Agents Chemother 2006; 50(1): 344-7.
[http://dx.doi.org/10.1128/AAC.50.1.344-347.2006] [PMID: 16377707]
[176]
Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006; 50(12): 4209-10.
[http://dx.doi.org/10.1128/AAC.00814-06] [PMID: 17000740]
[177]
Ouyang LQ, Wu HL, Liu YJ, et al. Simultaneous determination of metronidazole and tinidazole in plasma by using hplc-dad coupled with second-order calibration. Chin Chem Lett 2010; 21: 1223-6.
[http://dx.doi.org/10.1016/j.cclet.2010.04.016]
[178]
Singbal SS, Rataboli PV. Anaphylaxis and hypersensitivity syndrome reactions in increasing severity following repeated exposure to tinidazole. J Postgrad Med 2005; 51(3): 243-4.
[PMID: 16333209]
[179]
Brumfitt W, Hamilton-Miller JMT, Gooding A. Importance of methodology in determining bactericidal and bacteriostatic activities of azlocillin and ticarcillin against Pseudomonas aeruginosa. J Med Microbiol 1984; 17(1): 37-44.
[http://dx.doi.org/10.1099/00222615-17-1-37] [PMID: 6420572]
[180]
Leung ACT, Orange G, Henderson LS, Sleigh JD. Successful use of combined intraperitoneal azlocillin and aminogl ycoside in the treatment of dialysis associated Pseudomonas peritonitis. Perit Dial Int 1984; 4(2): 98-102.
[http://dx.doi.org/10.1177/089686088400400212]
[181]
Fu KP, Neu HC. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother 1978; 13(6): 930-8.
[http://dx.doi.org/10.1128/AAC.13.6.930] [PMID: 677860]
[182]
Pryka RD. An evaluation of the safety and efficacy of aztreonam versus azlocillin plus tobramycin in the treatment of pulmonary exacerbations in cystic fibrosis patients phd dissertation, university of utah 1987.
[183]
Frimodt-Möller N, Maigaard S, Toothaker RD, et al. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function. Antimicrob Agents Chemother 1980; 17(4): 599-607.
[http://dx.doi.org/10.1128/AAC.17.4.599] [PMID: 6446877]
[184]
Issell BF, Bodey GP, Weaver S. Clinical pharmacology of mezlocillin. Antimicrob Agents Chemother 1978; 13(2): 180-3.
[http://dx.doi.org/10.1128/AAC.13.2.180] [PMID: 646340]
[185]
Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL, Laskin JD. Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med 2008; 44(6): 1169-79.
[http://dx.doi.org/10.1016/j.freeradbiomed.2007.12.013] [PMID: 18206659]
[186]
Wasserman BN, Chronister TE, Stark BI, Saran BR. Ocular myasthenia and nitrofurantoin. Am J Ophthalmol 2000; 130(4): 531-3.
[http://dx.doi.org/10.1016/S0002-9394(00)00556-0] [PMID: 11024434]
[187]
Balfour JAB, Figgitt DP. Telithromycin. Drugs 2001; 61(6): 815-29.
[http://dx.doi.org/10.2165/00003495-200161060-00016] [PMID: 11398913]
[188]
Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50(4): 485-9.
[http://dx.doi.org/10.1136/gut.50.4.485] [PMID: 11889067]
[189]
Kasper M, Barth K. Bleomycin and its role in inducing apoptosis and senescence in lung cells - modulating effects of caveolin-1. Curr Cancer Drug Targets 2009; 9(3): 341-53.
[http://dx.doi.org/10.2174/156800909788166501] [PMID: 19442053]
[190]
O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14(1): 91-6.
[http://dx.doi.org/10.1093/annonc/mdg020] [PMID: 12488299]
[191]
Sanada M, Takagi Y, Ito R, Sekiguchi M. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair (Amst) 2004; 3(4): 413-20.
[http://dx.doi.org/10.1016/j.dnarep.2003.12.008] [PMID: 15010317]
[192]
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-26.
[http://dx.doi.org/10.1056/NEJMoa1104621] [PMID: 21639810]
[193]
Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology 2001; 58(6): 1016-20.
[http://dx.doi.org/10.1016/S0090-4295(01)01455-8] [PMID: 11744479]
[194]
Ask K, Décologne N, Asare N, et al. Distribution of nitroreductive activity toward nilutamide in rat. Toxicol Appl Pharmacol 2004; 201(1): 1-9.
[http://dx.doi.org/10.1016/j.taap.2004.04.006] [PMID: 15519603]
[195]
Yamazaki Y, Tanaka K, Nicholson B, et al. Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure. J Med Chem 2012; 55(3): 1056-71.
[http://dx.doi.org/10.1021/jm2009088] [PMID: 22185476]
[196]
Li Y, Wang S, Li Z. Design, synthesis, and insecticidal activity of novel neonicotinoid derivatives containing n-oxalyl groups. ARKIVOC 2009; XI: 152-64.
[197]
Bhardwaj S, Srivastava MK, Kapoor U, Srivastava LPAA. 90 days oral toxicity of imidacloprid in female rats: morphological, biochemical and histopathological evaluations. Food Chem Toxicol 2010; 48(5): 1185-90.
[http://dx.doi.org/10.1016/j.fct.2010.02.009] [PMID: 20146932]
[198]
Mizushina Y, Matsukage A, Sakaguchi K. The biochemical inhibition mode of bredinin-5′-monophosphate on DNA polymerase β. Biochim Biophys Acta 1998; 1403(1): 5-11.
[http://dx.doi.org/10.1016/S0167-4889(98)00027-5] [PMID: 9622583]
[199]
Sakaguchi K, Tsujino M, Yoshizawa M, Mizuno K, Hayano K. Action of bredinin on mammalian cells. Cancer Res 1975; 35(7): 1643-8.
[PMID: 1055633]
[200]
Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel) 2012; 5(8): 802-36.
[http://dx.doi.org/10.3390/ph5080802] [PMID: 24280676]
[201]
Srivastava PC, Streeter DG, Matthews TR, Allen LB, Sidwell RW, Robins RK. Synthesis and antiviral and antimicrobial activity of certain 1-β-D-ribofuranosyl-4,5-disubstituted imidazoles. J Med Chem 1976; 19(8): 1020-6.
[http://dx.doi.org/10.1021/jm00230a009] [PMID: 184281]
[202]
Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol 2009.2009681482
[http://dx.doi.org/10.1155/2009/681482] [PMID: 20052390]
[203]
Humble RW, Middleton DF, Banoub J, Ewing DF, Boa AN, Mackenzie G. A synthesis of bredinin (Mizoribine) from an acyclic precursor. Tetrahedron Lett 2011; 52: 6223-7.
[http://dx.doi.org/10.1016/j.tetlet.2011.09.085]
[204]
Ochiai C, Asano T, Takakura K, Fukuda T, Horizoe H, Morimoto Y. Mechanisms of cerebral protection by pentobarbital and nizofenone correlated with the course of local cerebral blood flow changes. Stroke 1982; 13(6): 788-96.
[http://dx.doi.org/10.1161/01.STR.13.6.788] [PMID: 7147293]
[205]
Hussain T, Siddiqui HL. Zia-ur-Rehman M, Masoom Yasinzai M, Parvez M. Anti-oxidant, anti-fungal and anti-leishmanial activities of novel 3-[4-(1H-imidazol-1-yl) phenyl]prop-2-en-1-ones. Eur J Med Chem 2009; 44(11): 4654-60.
[http://dx.doi.org/10.1016/j.ejmech.2009.06.038] [PMID: 19664864]
[206]
Liu Y, Zhuang X, Gou L, et al. Protective effects of nizofenone administration on the cognitive impairments induced by chronic restraint stress in mice. Pharmacol Biochem Behav 2013; 103(3): 474-80.
[http://dx.doi.org/10.1016/j.pbb.2012.09.009] [PMID: 23026061]
[207]
Shoham S, Groll AH, Petraitis V, Walsh TJ. systemic antifungal agents infectious diseases 4th 2017; 2: 1333-44.
[http://dx.doi.org/10.1016/b978-0-7020-6285-8.00156-8]
[208]
Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006; 49(11): 3315-21.
[http://dx.doi.org/10.1021/jm051197e] [PMID: 16722650]
[209]
Cupp-Vickery JR, Garcia C, Hofacre A, McGee-Estrada K. Ketoconazole-induced conformational changes in the active site of cytochrome P450eryF. J Mol Biol 2001; 311(1): 101-10.
[http://dx.doi.org/10.1006/jmbi.2001.4803] [PMID: 11469860]
[210]
Ji H, Zhang W, Zhou Y, et al. A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 2000; 43(13): 2493-505.
[http://dx.doi.org/10.1021/jm990589g] [PMID: 10891108]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 11
Year: 2020
Published on: 30 May, 2020
Page: [1130 - 1155]
Pages: 26
DOI: 10.2174/1389450121666200530203247
Price: $65

Article Metrics

PDF: 24
HTML: 5
PRC: 1